News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Renowned Dermatologist Dr. Neil Sadick Joins Histogen, Inc. Scientific Advisory Board

7/22/2010 12:07:47 PM

SAN DIEGO, July 22, 2010 – Histogen, Inc., a regenerative medicine company developing solutions based on the products of newborn cells grown under embryonic conditions, today announced that Dr. Neil Sadick has joined the Company’s Scientific Advisory Board.

A prominent dermatologist and researcher, Dr. Sadick holds positions as Clinical Professor of Dermatology at Weill Cornell Medical College and President of the Cosmetic Surgery Foundation, in addition to being the founder of Sadick Dermatology, a leading aesthetic medicine practice in New York. He is board certified in Dermatology, Cosmetic Surgery, Internal Medicine, and Hair Transplantation.

"We are excited to welcome Dr. Sadick to Histogen’s Scientific Advisory Board,” said Dr. Gail Naughton, CEO and Chairman of the Board for Histogen. “His clinical and research background and expertise will be invaluable as development and clinical studies of Histogen’s dermal filler and hair regrowth applications progress.”

Dr. Sadick is the recipient of the Jobst Award for Research in Vascular Diseases, American Cancer Society Research Award, American Medical Association’s Continuing Medical Education Award, and is a lead research physician for Merck Pharmaceutical, ESC Medical, Jobst Biersdorf, and Aesclepion. He has authored more than 500 peer-reviewed articles, written/edited more than 10 books on cosmetic surgery, hair and vein treatment, and contributed more than 75 medical book chapters.

“Histogen’s technology, and its numerous applications in aesthetic medicine, are truly unique and exciting,” said Dr. Sadick. “As a member of the Company’s SAB, I look forward to contributing to the development of Histogen’s near-term applications, particularly in the areas of cosmetic surgery and hair restoration where these next-generation products can have a large impact.”

About Histogen

Histogen, launched in 2007, seeks to redefine regenerative medicine by developing a series of high value products that do not contain embryonic stem cells or animal components. Through Histogen's proprietary bioreactors that mimic the embryonic environment, newborn cells are encouraged to naturally produce the vital proteins and growth factors from which the Company has developed its rich product portfolio. Histogen has two product families – a proprietary liquid complex of embryonic-like proteins and growth factors, and a human Extracellular Matrix (ECM) material, ExCeltrix. For more information, please visit

Read at

comments powered by Disqus